Nitrogen In Aglycone Moiety Patents (Class 536/17.9)
  • Patent number: 10519475
    Abstract: Provided herein are genetically modified yeast cells capable of producing one or more human milk oligosaccharides. The yeast cells include one or more heterologous nucleic acids that encode enzymes of a human milk oligosaccharide biosynthetic pathway. The yeast cells do not include a heterologous nucleic acid encoding a fucokinase. Also provided are fermentation compositions including the disclosed genetically modified yeast cells, and related methods of producing and recovering human milk oligosaccharides generated by the yeast cells.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: December 31, 2019
    Assignee: Amyris, Inc.
    Inventors: Jessica Walter, Joshua A. Lerman, Michael Leavell, Benjamin Yap
  • Patent number: 10081653
    Abstract: The present invention provides a method for preparing a 6-aminohexyl lactoside-NOTA conjugate. The preparation method comprises brominating perbenzoylated lactose with hydrobromic acid; glycosylating 6-azidohexanol to obtain 6-azidohexyl perbenzoyl lactoside; and deprotecting this precursor in two steps to obtain 6-aminohexyl lactoside and conjugating 6-aminohexyl lactoside to NCS-benzyl-NODA GA (i.e. 2,2?-(7-(1-carboxy-4-((4-isothiocyanate benzyl) amino)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl) diacetic acid) in triethyl amine as an alkaline solvent, to obtain a 6-aminohexyl lactoside-NCS-benzyl-NODA GA conjugate. In this novel preparation method, no deglycosylated side product is produced, such that the yield is considerably increased to 46%. Therefore, the method is suitable for future massive production since the requirement for repeated preparations for massive production is reduced, and the impurities produced in the previously scaled-up preparation process are not present.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: September 25, 2018
    Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN, R.O.C
    Inventors: Rui-Yu Chen, Yan-Feng Jiang, Mei-Hui Wang, Jen-Tsung Wang, Wuu-Jyh Lin
  • Patent number: 10030006
    Abstract: Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: July 24, 2018
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Brian S. J. Blagg, Huiping Zhao
  • Patent number: 9045517
    Abstract: There is provided a method of glycosylating an aminocoumarin compound comprising conjugating a sugar to the 4?-OH position of the core of the aminocoumarin compound. Also provided is an aminocoumarin compound glycosylated at the 4?-OH position of the core of the aminocoumarin compound. Further aspects of this invention provide this compound for use in therapy, more particularly for use as an antibiotic, or in anticancer treatment.
    Type: Grant
    Filed: October 17, 2011
    Date of Patent: June 2, 2015
    Assignee: University College London
    Inventor: Min Yang
  • Publication number: 20150139998
    Abstract: The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection.
    Type: Application
    Filed: March 4, 2013
    Publication date: May 21, 2015
    Inventors: Johannes Huebner, Otto Holst, Christian Theilacker, Karolina Kruszynska, Stefan Geiss-Liebisch, Agnieszka Beczala
  • Publication number: 20150141352
    Abstract: The present invention relates to a bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide, an analogue thereof, a derivative thereof or a pharmaceutically acceptable salt thereof. In contrast to existing passive therapeutic agents which center on bone absorption suppression based on mechanisms for reducing osteoclast functionality, the composition comprising muramyl dipeptide of the present invention promotes the differentiation of osteoblasts, which are bone forming cells, and can advantageously be used in various diseases where bone formation is required as an active therapeutic agent that does not affect osteoclast.
    Type: Application
    Filed: November 1, 2012
    Publication date: May 21, 2015
    Applicant: SNU R&DB FOUNDATION
    Inventors: Seung Hyun Han, Ok-Jin Park, Cheol-Heul Yun
  • Publication number: 20150133647
    Abstract: The application discloses a method for producing anomerically protected glycosidic oligosaccharide derivatives comprising the step of culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor. The application further discloses a method for producing an oligosaccharide comprising the steps of: (a) culturing, in a culture medium containing an anomerically protected lactose acceptor, a genetically modified cell having a recombinant gene that encodes a glycosyl transferase that can transfer a glycosyl residue of an activated sugar nucleotide to said lactose acceptor to produce an anomerically protected glycosidic oligosaccharide derivative, then (b) removing/deprotecting the anomeric protective group.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 14, 2015
    Applicant: Glycom A/S
    Inventors: Pauline Peltier-Pain, Gyula Dekany, Rémy Dureau, Christian Risinger, Markus Hederos, Elise Champion
  • Publication number: 20150126718
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: December 30, 2014
    Publication date: May 7, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 9018363
    Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: April 28, 2015
    Assignee: Dow AgroSciences LLC
    Inventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
  • Publication number: 20150110808
    Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
    Type: Application
    Filed: December 21, 2012
    Publication date: April 23, 2015
    Applicant: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
  • Publication number: 20150080232
    Abstract: This invention provides nucleoside triphosphate analogues having the structure: wherein B is a base and is adenine, guanine, cytosine, uracil or thymine, wherein R? is an OH or an H, and wherein R? is azidomethyl, a hydrocarbyl, or a substituted hydrocarbyl, and which has a Raman spectroscopy peak with wavenumber from 2000 cm?1 to 2300 cm?1 or a Fourier transform-infrared spectroscopy spectroscopy peak with wavenumber from 2000 cm?1 to 2300 cm?1, and also to methods of DNA sequencing and SNP detection.
    Type: Application
    Filed: May 23, 2012
    Publication date: March 19, 2015
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Jingyue Ju, Jian Wu, Zengmin Li
  • Patent number: 8981049
    Abstract: Improved methods of native chemical ligation are provided. The methods involve reacting a thioacid (e.g. a peptide thioacid) with an aziridinyl compound (e.g. an aziridinyl peptide) under mild conditions without the use of protecting groups, and without requiring that a cysteine residue be present in the ligation product. Initial coupling of the thioacid and the aziridinyl compound yields a ligation product which contains an aziridinyl ring. Subsequent opening of the aziridinyl ring (e.g. via a nucleophilic attack) produces a linearized and modified ligation product.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: March 17, 2015
    Assignee: Washington State University
    Inventor: Philip Garner
  • Publication number: 20150072944
    Abstract: Proton mopping is a new anti-cancer therapeutic approach that disrupts cancer's immunologic balance. It results in the alteration of the pHi/pHe ratio (intracellular-extracellular) of the cancer cell, leading cancer to either normalcy or apoptosis. This technology deploys a chemical compound that has two parts, a glucose part to guide the molecule to the cancer site and a proton neutralizer to mop up the protons. Proof of the validity of this therapeutic approach came after using an existing chemical compound 2-[2(2-Aminoethoxy)ethoxy]ethyl a-D-mannopyranoside, C12H25NO8, which has the above mentioned properties. This compound is of the class of functionalized PEGylated glycosides, which are ligands for conjugation to biological molecules.
    Type: Application
    Filed: September 8, 2014
    Publication date: March 12, 2015
    Inventor: Michael Theodore Lytinas
  • Publication number: 20150071960
    Abstract: Glycosphingolipids (GSLs) bearing ?-glucose (?-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with ?-glucose (?-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with ?-galactose (?-Gal) are disclosed. GSLs bearing ?-glucose (?-Glc) and derivatives of ?-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with ?-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with ?-Glc and derivatives thereof are provided.
    Type: Application
    Filed: September 8, 2014
    Publication date: March 12, 2015
    Inventors: Chi-Huey WONG, Alice L. Yu, Kun-Hsien Lin, Tai-Na Chen
  • Publication number: 20150057240
    Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Application
    Filed: February 8, 2013
    Publication date: February 26, 2015
    Inventors: Brian S. J. Blagg, Bhaskar Reddy Kusuma, Teather Sundstrom
  • Patent number: 8961931
    Abstract: A 18F-labeled monomeric galactose derivative is provided as a tomography probe. The derivative is a positron emission tomography (PET) probe. The derivative has high affinity and good stability in animal's body. The derivative can be an alternative glucose metabolism imaging agent used in clinic examination and quantification.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: February 24, 2015
    Assignee: Institute of Nuclear Energy Research, Atomic Energy Council
    Inventors: Ting-Shien Duh, Wuu-Jyh Lin, Jenn-Tzong Chen, Li-Yuan Huang, Hsin-Ell Wang, Chuan-Lin Chen, Wen-Yi Chang, Hao-Wen Kao
  • Publication number: 20150051371
    Abstract: Provided herein are water-soluble carbohydrate polymers which are monoderivatized at their reducing terminus, such that the carbohydrate polymers can be selectively conjugated at a single location. Also provided are methods of preparation and conjugation of the monoderivatized carbohydrate polymers.
    Type: Application
    Filed: January 29, 2014
    Publication date: February 19, 2015
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Antoni Kozlowski, Samuel P. McManus, Xiaoming Shen
  • Publication number: 20150050297
    Abstract: The present invention relates to a use of at least one glycosylated tetrafunctional amphiphilic block copolymer, as immune adjuvant.
    Type: Application
    Filed: March 1, 2013
    Publication date: February 19, 2015
    Inventor: Bruno Pitard
  • Publication number: 20150051387
    Abstract: Disclosed are water-soluble platinum complexes for tumor treatment and preparation method, said platinum complexes being shown as formula (I); The present platinum complexes exhibiting superior cytotoxicity and efficacy compare to the clinical drug oxaliplatin, the design strategy of the present platinum complexes is to enhance the solubility and stability favor its clinical use.
    Type: Application
    Filed: June 22, 2012
    Publication date: February 19, 2015
    Applicant: GUDUI BIOPHARMA TECHNOLOGY INC.
    Inventors: Yiqiang Wang, Yang Liu
  • Publication number: 20150018537
    Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.
    Type: Application
    Filed: April 18, 2014
    Publication date: January 15, 2015
    Applicant: Reliable Biopharmaceutical Corporation
    Inventors: Sourena NADJI, James T. Smoot, Joseph A. Vanartsdalen
  • Publication number: 20150018292
    Abstract: The present invention relates to a novel alkaloid and novel bioactive alkaloid fractions derivable from Ribes preferably selected among Ribes Rubrum and Ribes nigrum; methods of manufacturing such bioactive Ribes alkaloid fractions and their use for the inhibition of IKK-?, PDE4 and/or PDE5 and in addition their promoting effect on mitochondrial biogenesis and function; their therapeutic or non-therapeutic applications as nutritive or medicinal products in the management of conditions associated with impaired mitochondrial function or IKK-?, PDE4 and/or PDE5 activity, such as inflammation, neurodegeneration, dyslipidemia, type 2 diabetes mellitus, impaired wound healing, sarcopenia and other conditions associated with muscle dysfunction or tiredness and fatigue, or where optimization of muscular or cognitive function is desired; extracts, juices or concentrates of Ribes comprising such alkaloids; compostions comprising such alkaloids, including pharmaceutical compositions, nutritive product such as functional
    Type: Application
    Filed: July 14, 2014
    Publication date: January 15, 2015
    Inventors: Morten Sloth Weidner, Ida Sloth Weidner
  • Publication number: 20140377291
    Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.
    Type: Application
    Filed: February 7, 2013
    Publication date: December 25, 2014
    Inventors: Michael A. Fischbach, Jeffrey A. Bluestone, Cristina Penaranda, Laura Brown, Jon Clardy
  • Patent number: 8906868
    Abstract: The present invention relates to antimicrobial agents. Some embodiments include compounds, compositions, methods of preparation, and methods of treatment using new aminoglycosides and aminoglycoside derivatives.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: December 9, 2014
    Assignee: Rempex Pharmaceuticals, Inc.
    Inventors: Tomasz W. Glinka, Olga Rodny
  • Publication number: 20140357590
    Abstract: A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5? position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.
    Type: Application
    Filed: August 18, 2014
    Publication date: December 4, 2014
    Inventors: Timor BAASOV, Dana Atia-Glikin, Jeyakumar Kandasamy, Valery Belakhov
  • Publication number: 20140349952
    Abstract: The present invention relates to new anti-infectious compounds consisting of (i) a polar head having from one to three mannose, dimannose or trimannose moieties, which is coupled through an appropriate linker to (ii) a single lipid chain of at least 17 carbon atoms of length. Pharmaceutical compositions and therapeutic uses thereof are also provided.
    Type: Application
    Filed: November 14, 2012
    Publication date: November 27, 2014
    Inventors: Rachid Baati, Laure Dehuyser, Christopher Mueller, Evelyne Schaeffer, Alain Wagner
  • Publication number: 20140348786
    Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.
    Type: Application
    Filed: August 7, 2014
    Publication date: November 27, 2014
    Inventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
  • Patent number: 8895519
    Abstract: A new class of pseudo-trisaccharide aminoglycosides having an alkyl group at the 5? position, exhibiting efficient stop codon mutation readthrough activity, low cytotoxicity and high selectivity towards eukaryotic translation systems are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders, as well as processes of preparing these aminoglycosides. The disclosed aminoglycosides can be represented by the general formula I: or a pharmaceutically acceptable salt thereof, wherein R1 is selected from the group consisting of alkyl, cycloalkyl and aryl; and all other variables and features are as described in the specification.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: November 25, 2014
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Timor Baasov, Dana Atia-Glikin, Jeyakumar Kandasamy, Valery Belakhov
  • Patent number: 8883746
    Abstract: Disclosed are novel ?-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation methods thereof, and pharmaceutical compositions for use in an immune adjuvant containing the same as an active ingredient. The derivatives, in which the amide moiety of ?-GalCer is bioisosterically replaced with a triazole moiety, direct cytokine secretion toward IL-4 rather than IFN-?and thus can be used as a therapeutic for autoimmune diseases regulated by IL-4, such as type 1 diabetes and multiple sclerosis.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: November 11, 2014
    Assignee: SNU R&DB Foundation
    Inventors: Chang-Yuil Kang, SangHee Kim, Hyun-Jun Youn, Yoon-Sook Lee, Kyoo-A Lee, Taeho Lee, Dong Jae Baek, Minjae Cho
  • Patent number: 8877906
    Abstract: The invention provides amphiphiles for manipulating membrane proteins. The amphiphiles can feature carbohydrate-derived hydrophilic groups and branchpoints in the hydrophilic moiety and/or in a lipophilic moiety. Such amphiphiles are useful as detergents for solubilization and stabilization of membrane proteins, including photosynthetic protein superassemblies obtained from bacterial membranes.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: November 4, 2014
    Assignees: Wisconsin Aumni Research Foundation, UChicago Argonne, LLC
    Inventors: Samuel Helmer Gellman, Pil Seok Chae, Phillip D. Laible, Marc J. Wander
  • Publication number: 20140309179
    Abstract: A method of treating or preventing a retinopathy such as glaucoma in a human patient in need thereof comprising administering one or more gangliosides to the patient.
    Type: Application
    Filed: April 17, 2014
    Publication date: October 16, 2014
    Applicant: LZ Therapeutics, Inc.
    Inventors: Jay S. Schneider, Gerri Henwood, Robert Florentine, David W. Anderson
  • Patent number: 8859509
    Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: October 14, 2014
    Assignee: Yale University
    Inventors: David Spiegel, Ryan Murelli, Andrew Zhang
  • Publication number: 20140303359
    Abstract: Disclosed is a method for selective synthesis of 1,2-cis-?-linked glycosides which does not require the use of the specialized protecting group patterns normally employed to control diastereoselectivity. Thioglycoside acceptors can be used, permitting iterative oligosaccharide synthesis. The approach eliminates the need for lengthy syntheses of monosaccharides possessing highly specialized and unconventional protecting group patterns.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 9, 2014
    Applicant: Trustees of Tufts College
    Inventors: Clay S. Bennett, An-Hsiang Adam Chu
  • Patent number: 8852630
    Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: October 7, 2014
    Assignee: Yale University
    Inventors: David Spiegel, Ryan Murelli, Andrew Zhang
  • Publication number: 20140274930
    Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides processes for making the compounds described herein. Furthermore, the present invention provides a composition comprising the compounds described herein, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The present invention also provides methods of treating or preventing bacteria infection in a subject, comprising administering to the subject an effective amount of the compound or the composition described herein.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Evelyne Dietrich, Carl Poisson, Michel Gallant, Stephanie Lessard, Bingcan Liu, Sanjoy Kumar Das, Yeeman Ramtohul, Thumkunta Jagadeeswar Reddy, Julien Martel, Frederic Vallee, Jean-Francois Lévesque
  • Publication number: 20140274798
    Abstract: Substrates are provided that include compounds suitable for detecting the activity of an enzyme such as a lysosomal storage enzyme where the substrates include: a sugar moiety; a linker moiety allowing the conjugation of sugar moiety with the remaining structure of the substrate; and two or more fatty acid chains or derivatives thereof at least one of which is sufficiently structured to provide improved solubility in aqueous or organic solvent systems. Also provided are methods for using substrates for detecting enzymatic activity using the inventive substrates.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicants: University of Washington Through its Center for Commercialization, PerkinElmer Health Sciences, Inc.
    Inventors: Alexander Cherkassky, Jason Cournoyer, Michael Gelb
  • Patent number: 8835613
    Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: September 16, 2014
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The University of Birmingham, of Edgbaston
    Inventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr Illarionov, Gurdyal S. Besra
  • Publication number: 20140256923
    Abstract: A compound represented by the following Structural Formula (A) or a salt thereof. The compound or the salt thereof is suitably produced from a microorganism belonging to the genus Saccharothrix and can be suitably used as a prostaglandin production inhibitor.
    Type: Application
    Filed: April 29, 2014
    Publication date: September 11, 2014
    Applicant: Microbial Chemistry Research Foundation
    Inventors: Koichi NAKAE, Fukiko KOJIMA
  • Publication number: 20140256015
    Abstract: An objective of the present invention is to provide a caged compound that can be photoactivated selectively for specific target cell types and can be used in an individual organism. The objective can be achieved by a compound represented by general formula K-Q-X, which is prepared by binding bioactive substance X, photocleavable protecting group Q, and compound K, which can be an enzyme substrate and is dissociated from Q-X by an enzyme reaction, wherein: Q is a protecting group that is photocleaved by light with a specific wavelength and then dissociated from X, when K is not bound thereto; X is a substance that does not express bioactivity when Q is bound thereto, but expresses bioactivity when Q is dissociated therefrom; and K is dissociated from Q by the above enzyme, so as to form a compound represented by Q-X.
    Type: Application
    Filed: February 25, 2014
    Publication date: September 11, 2014
    Applicant: Toho University
    Inventors: Toshiaki FURUTA, Masaki SONE, Akinobu SUZUKI, Eri OKA
  • Publication number: 20140243512
    Abstract: In a first embodiment the present invention relates to a sorbent comprising a porous inorganic solid support material having on its surface a film of a crosslinked polyvinylamine comprising derivatized amine groups and amine groups binding to the surface of the support material via electron donor/acceptor interactions. In a second embodiment the present invention relates to a sorbent comprising a solid support material, the surface of which comprises a residue of a general formula (I), wherein the residue is attached via a covalent single bond to a functional group on the surface of either the bulk solid support material itself or of a polymer film on the surface of the solid support material. Furthermore, the present invention relates to the use of the sorbents according to the invention for the purification of organic molecules, in particular pharmaceutical active compounds, preferably in chromatographic applications.
    Type: Application
    Filed: September 17, 2012
    Publication date: August 28, 2014
    Applicant: INSTRACTION GMBH
    Inventors: Markus Arendt, Björn Degel, Thomas Schwarz, Gerhard Stumm, Martin Welter
  • Publication number: 20140234876
    Abstract: The present invention provides a hapten derivative and conjugate of a natural high intensity sweetener containing hydroxyl groups. The conjugate can be used to produce antibodies specific against the natural high intensity sweetener. The present invention further provides a kit and method for detecting and quantifying the natural high intensity sweetener in a sample.
    Type: Application
    Filed: June 22, 2012
    Publication date: August 21, 2014
    Applicant: PURECIRCLE SDN BHD
    Inventors: Jose Antonio Gabaldon Hernandez, Estrella Nunez Delicado, Rosa Puchades Pla, Angel Maquiera, Eva Maria Brun Sanchez, Avetik Markosyan
  • Publication number: 20140234364
    Abstract: The present invention relates to the total chemical synthesis of the monosaccharide 35# (R??H), the disaccharide 36# (R??H; R??H), the trisaccharide 37# (R??H; R??H; R???H) and the tetrasaccharide 1# (R??H; R??H; R???H) of the following general formula wherein R represents —Y—NH2Y represents a linker R? is H or R? is H or R?? is H or of the lipopolysaccharide from Neisseria meningitidis, as well as to the trisaccharide 37# and the tetrasaccharide 1#, to vaccines containing at least one of the saccharides 1#, 35#, 36#, and 37# and to the use of such vaccine for immunization against diseases caused by infection with bacteria containing the tetrasaccharide ?-GlcNAc-(1?2)-?-Hep-(1?3)-?-Hep-(1?5)-?-Kdo or the trisaccharide ?-Hep-(1?3)-?-Hep-(1?5)-?-Kdo or ?-GlcNAc-(1?2)-?-Hep-(1?3)-?-Hep, especially for immunization against meningitis, septicaemia, pneumonia and nasopharyngitis caused by Neisseria meningitidis.
    Type: Application
    Filed: September 24, 2012
    Publication date: August 21, 2014
    Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Peter H. Seeberger, You Yang, Chakkumkal Anish, Anika Reinhardt
  • Publication number: 20140235536
    Abstract: A composition in the form of an injectable aqueous solution, the pH of which is from 6.6 to 7.8, comprises at least: a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and b) an anionic compound bearing carboxylate charges and hydrophobic radicals. The composition may also include a prandial insulin.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 21, 2014
    Applicant: ADOCIA
    Inventors: Olivier SOULA, Richard CHARVET, Alexandre GEISSLER
  • Publication number: 20140227296
    Abstract: The invention is directed to compositions and methods related to proteins that are physically associated with ceramide-like glycolipids for use as activators of NKT cells. The compositions and methods of the present invention are useful for the prevention and treatment of diseases.
    Type: Application
    Filed: March 14, 2013
    Publication date: August 14, 2014
    Inventors: Steven A. Porcelli, Maurice Zauderer
  • Patent number: 8802654
    Abstract: Herein are disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates are useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues present on the cell surface of the cell to be infected by the virus.
    Type: Grant
    Filed: July 5, 2010
    Date of Patent: August 12, 2014
    Assignee: Adenovir Pharma AB
    Inventors: Olov Sterner, Ulf Ellervik, Karolina Aplander, Anders Carlsson
  • Publication number: 20140221633
    Abstract: The present invention provides a one-pot method of preparing an unprotected ?-O-glycolipid. The first step involves contacting a protected ?-iodo sugar with a catalyst and a lipid comprising a hydroxy group, under conditions sufficient to prepare a protected ?-O-glycolipid. The second step involves deprotecting the protected ?-O-glycolipid under conditions sufficient to prepare the unprotected ?-O-glycolipid, wherein the contacting and deprotecting steps are performed in a single vessel. The present invention also provides a one-pot method of preparing an unprotected ?-O-glycolipid following the steps for the preparation of the unprotected ?-O-glycolipid.
    Type: Application
    Filed: January 6, 2014
    Publication date: August 7, 2014
    Inventors: Jacquelyn Gervay-Hague, Wenjun Du, Suvarn S. Kulkarni, Matthew Schombs
  • Patent number: 8796229
    Abstract: Compounds and methods for use in selectively inhibiting a lytic enzyme based on feedback inhibition are described. The conjugated compound serves as a substrate for a lytic enzyme. Cleavage of the conjugated compound by the lytic enzyme releases an inhibitor of the enzyme.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: August 5, 2014
    Assignee: University of Georgia Research Foundation, Inc.
    Inventors: Geert-Jan Boons, Jun Guo
  • Publication number: 20140187499
    Abstract: The invention relates to substituted anionic compounds consisting of a backbone made up of a discrete number u of between 1 and 8 (1?u?8) of identical or different saccharide units, linked via identical or different glycosidic bonds, said saccharide units being chosen from the group consisting of pentoses, hexoses, uronic acids, N-acetylhexosamines in cyclic form or in open reduced form, which are randomly substituted. It also relates to the process for the preparation thereof and to the pharmaceutical compositions comprising same.
    Type: Application
    Filed: November 13, 2013
    Publication date: July 3, 2014
    Inventors: Gérard SOULA, Emmanuel DAUTY, Richard CHARVET
  • Patent number: 8765692
    Abstract: Modified glycolipid compounds are provided. Also disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, and methods suitable for labeling NKT cells.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: July 1, 2014
    Assignees: The Scripps Research Institute, The University of Chicago, Bringham Young University
    Inventors: Paul B. Savage, Luc Teyton, Albert Bendelac
  • Publication number: 20140179761
    Abstract: The present invention provides targeting lipids of structure L100-linker-L101??(CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.
    Type: Application
    Filed: October 22, 2013
    Publication date: June 26, 2014
    Applicant: Tekmira Pharmaceuticals Corporation
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Jayaprakash K. Narayanannair, Muthusamy Jayaraman
  • Patent number: 8759501
    Abstract: The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: June 24, 2014
    Assignee: Genzyme Corporation
    Inventors: Yunxiang Zhu, Seng H. Cheng, Canwen Jiang, Luis Z. Avila